Abstract
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and challenging disease characterized by the deposition of misfolded transthyretin protein in the myocardial interstitium. Until recently, treatment options for ATTR-CM have been limited, with tafamidis emerging as the primary therapeutic agent targeting the stabilization of transthyretin tetramers to prevent amyloid fibril formation. However, advancements in understanding ATTR-CM's underlying mechanisms have led to developing novel therapeutic strategies to address various aspects of the disease process. This review explores the current landscape of therapeutic options for ATTR-CM. It encompasses strategies ranging from inhibiting TTR synthesis using RNA silencing methods such as small interfering RNA (e.g. HELIOS-B trial with vutrisiran) and antisense oligonucleotides (e.g. CARDIO-TTRansform trial with eplontersen) to gene-editing technologies like CRISPR/Cas9 (e.g. MAGNITUDE trial with NTLA-2001). Additionally, it explores TTR stabilization approaches beyond tafamidis, such as next-generation acoramidis, which showed success in the ATTRibute-CM trial. It also examines therapies promoting TTR degradation and removal, which includes the use of monoclonal antibodies (e.g. DepleTTR-CM with ALXN2220) and other compounds like doxycycline or epigallocatechin-3-gallate (a green tea component), which, despite long-standing recognition, remain underexplored. Novel approaches such as seeding inhibitors and molecular tweezers, which aim to inhibit TTR fibril

This publication has 29 references indexed in Scilit: